Selin Kurnaz is an accomplished entrepreneur and engineer, and the founder of Massive Bio, a company providing global access to cancer clinical trials and overcoming geographic and financial barriers. She previously helped establish EY’s Private Equity Value Creation team, focusing on healthcare investments, and has over a decade of experience in management consulting, combining strategy, operations, and transactions to drive growth and efficiency in healthcare.
Selin holds multiple engineering degrees from the University of Michigan and has a strong background in mathematics. Beyond Massive Bio, she seeks to innovate across industries, including energy and transportation. Her career reflects a combination of professional ambition, strategic insight, and personal dedication to transforming healthcare access worldwide.
The 100 CEOs featured here reflect the diversity and complexity of modern oncology leadership. In 2025, some lead the world’s largest cancer institutions; others guide specialized societies or emerging innovators. What unites them is responsibility: for millions of patients, for the integrity of science, and for the future direction of cancer care globally.
This list is not a celebration of power, but a recognition of stewardship, accountability, and impact – and of the leaders whose choices continue to shape the fight against cancer. For the many deserving individuals not mentioned in this list, we will continue to acknowledge, honor and elevate your voices in our daily publications from across the world.
See the full list of The 100 Influential CEOs in Oncology in 2025 and stay tuned for other special category nominations
